---
title: "China Resources Pharma Subsidiary Starts Pre-Bidding for Potential Share Issuance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302114112.md"
description: "China Resources Pharmaceutical Group's subsidiary, CR Pharmaceutical Commercial Group, has initiated pre-bidding for a potential new share issuance via the China Beijing Equity Exchange. The move aims to raise capital under state-owned asset trading regulations. Pre-bidding started on October 16, 2026, but no binding agreements exist yet, and the transaction may not proceed. Investors are urged to exercise caution as the plan requires further approvals."
datetime: "2026-10-16T13:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302114112.md)
  - [en](https://longbridge.com/en/news/302114112.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302114112.md)
generator: "portal-rs"
---

# China Resources Pharma Subsidiary Starts Pre-Bidding for Potential Share Issuance

The latest update is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).

China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial Group Company Limited, is pursuing a potential issuance of new shares via public bidding through the China Beijing Equity Exchange. The move is intended to raise fresh capital under China’s regulatory framework for state-owned asset trading, with the size of the issuance and proceeds to be determined based on market conditions.

The pre-bidding process for the proposed share issuance commenced on 16 October 2026, marking an initial step toward a formal public bidding phase on the exchange. However, the company stressed that no binding agreements have yet been signed and that the transaction may not proceed, urging shareholders and potential investors to exercise caution as the capital-raising plan remains subject to further approvals and closing conditions.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical conglomerate with a significant presence in China’s healthcare sector. Through subsidiaries such as China Resources Pharmaceutical Commercial Group Company Limited, it operates in pharmaceutical distribution and related commercial services, serving hospitals, pharmacies and other medical institutions across the country.

The group’s commercial arm, CR Pharmaceutical Commercial, focuses on capital-raising and equity transactions in accordance with Chinese regulations on state-owned asset trading. Its activities are subject to oversight by Hong Kong listing rules and the Securities and Futures Ordinance, reflecting the company’s dual exposure to mainland and Hong Kong regulatory regimes.

**Average Trading Volume:** 8,018,594

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$29.03B

Learn more about 3320 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [01508.HK](https://longbridge.com/en/quote/01508.HK.md)

## Related News & Research

- [China Resources Pharmaceutical Unit Secures Approval for RMB 10 Billion Corporate Bond Issuance](https://longbridge.com/en/news/305661943.md)
- [China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion](https://longbridge.com/en/news/303715107.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [The Tesla Cybercab Is Now Available In Dallas](https://longbridge.com/en/news/306159915.md)
- [China Resources Pharmaceutical Completes RMB 800 Million Medium-Term Note Issuance](https://longbridge.com/en/news/302856714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**